渤健公司 BIIB 深 滬
等待開盤 08-21 09:30:00 美东时间
214.35
-7.210
-3.25%
華盛通- 最 高221.29
- 今 開217.98
- 成交量 80.86万股
- 最 低 214.16
- 昨 收 221.56
- 總市值 316.71亿
- 52周最高 222.15
- 市盈率 靜 24.39
- 換手率 0.55%
- 52周最低 133.53
- 委 比 60.00%
- 總股本 1.48亿
- 歷史最高 468.55
- 量 比 1.12
- 振 幅 3.22%
- 歷史最低 61.605
- 每 手 1
- 風險率 21.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.
08-14 01:18
Regeneron, Tenet leads top healthcare companies with highest earnings beats
As corporate earnings season progresses, investors are tracking sector performance metrics to gauge underlying healthcare demand and corporate efficiency. For the healthcare sector, spanning critical ...
08-12 18:54
Biogen Completes Acquisition of RayThera Inc.
Biogen completed the acquisition of RayThera Inc., a biotech company focused on small-molecule therapies in immunology. The deal strengthens Biogen’s immunology portfolio, adding assets targeting immune-mediated conditions. RayThera’s lead program entered Phase 1 development in July 2026. Biogen emphasizes its commitment to innovation and growth in immunology, highlighting the acquisition as a strategic move to diversify and strengthen its pipeli...
08-06 22:15
生物科技IPO热潮持续!心血管药企Braveheart(BRVE.US)募资扩大至3.825亿美元，发行价突破指引上限
生物科技公司Braveheart在美国IPO规模扩大后，筹集资金3.825亿美元。
08-06 16:28
解码致病通路 加快研发突破
（来源：中国医药报） 转自：中国医药报 近年来，与中枢神经系统（CNS）疾病相关的全球疾病负担持续上升，造成巨大的经济影响。预计到2030年，仅心理健康问题造...
08-06 07:59
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96. Revenue Tops Expectations On Growth Across Key Products The Alzheimer’s drug maker reported revenues of $2.736 billion, beati...
07-30 01:36
